Biblio

Found 6 results

Filters: Author is Bilsky, Edward J [Clear All Filters]

2018

Streicher JM, Bilsky EJ. 2018. Peripherally Acting μ-Opioid Receptor Antagonists for the Treatment of Opioid-Related Side Effects: Mechanism of Action and Clinical Implications.. J Pharm Pract. 31(6):658-669.

2017

Lei W, Mullen N, McCarthy S, Brann C, Richard P, Cormier J, Edwards K, Bilsky EJ, Streicher JM. 2017. Heat-shock protein 90 (Hsp90) promotes opioid-induced anti-nociception by an ERK mitogen-activated protein kinase (MAPK) mechanism in mouse brain.. J Biol Chem. 292(25):10414-10428.

2016

Zhang Y, Williams DA, Zaidi SA, Yuan Y, Braithwaite A, Bilsky EJ, Dewey WL, Akbarali HI, Streicher JM, Selley DE. 2016. 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion.. ACS Chem Neurosci. 7(3):297-304.

2015

Stevenson GW, Luginbuhl A, Dunbar C, LaVigne J, Dutra J, Atherton P, Bell B, Cone K, Giuvelis D, Polt R et al.. 2015. The mixed-action delta/mu opioid agonist MMP-2200 does not produce conditioned place preference but does maintain drug self-administration in rats, and induces in vitro markers of tolerance and dependence.. Pharmacol Biochem Behav. 132:49-55.

2014

Zhang Y, Braithwaite A, Yuan Y, Streicher JM, Bilsky EJ. 2014. Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.. Eur J Pharmacol. 736:124-30.

2013

Podolsky AT, Sandweiss A, Hu J, Bilsky EJ, Cain JP, Kumirov VK, Lee YSun, Hruby VJ, Vardanyan RS, Vanderah TW. 2013. Novel fentanyl-based dual μ/δ-opioid agonists for the treatment of acute and chronic pain.. Life Sci. 93(25-26):1010-6.